Company: IMRX
Filing Date: 2025-09-24
Form Type: 8-K
Source: 0001104659-25-092957
Chunk: 5

Company: Immuneering Corp
Filing Date: 2025-09-24
Form: 8-K
Item: Item 8.01
Chunk 5
---
Item 8.01. Other Events.

On September 24, 2025, the Company announced updated interim data from
its ongoing Phase 2a clinical trial arm evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein
kinase kinase (or MEK) inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel (“mGnP”) in first-line pancreatic
cancer patients, which is part of Company’s ongoing Phase 1/2a clinical trial of atebimetinib in patients with advanced RAS- and/or
RAF-mutant solid tumors.

The Company announced that, as of a cutoff date of August 26, 2025
(the “ Cutoff Date”), 86% overall survival (“ OS”) and 53% progression free survival (“ PFS”) were observed
in the initial intent-to-treat population of 34 patients dosed at the 320 mg once-daily dose level of atebimetinib in combination with
mGnP (the “320 mg ITT Population”), with a median follow up time of nine months. Estimates of standard of care (described
below) suggest a ~47% OS and ~29% PFS at nine months. As of the Cutoff Date, the median OS of the 320 mg ITT Population had not been reached
and the median PFS was 9.6 months..

As of the Cutoff Date, 94% OS and 70% PFS were observed in the 320
mg ITT Population at six months. The standard of care (described below) reported a 67% OS and 44% PFS at six months.

All data reported by the Company were from the same patient cohort
(N=34) as the Company previously reported in June 2025.

The estimates of (and other references to) standard of care set forth
above with respect to the nine-month follow-up data were extrapolated and reconstructed by the Company based on the publicly available
third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel. The estimates of (and other references to) standard of care set forth
above with respect to the six-month follow-up data were reported out directly from the publicly available third-party MPACT pivotal trial
data for gemcitabine/nab-paclitaxel. The Company’s Phase 1/2a